Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
hexacyclonate
|
| gptkbp:ATCCode |
N06BX06
|
| gptkbp:CASNumber |
510-11-2
|
| gptkbp:developedBy |
1970s
|
| gptkbp:drugClass |
psychostimulant
cognitive enhancer |
| gptkbp:hasMolecularFormula |
C13H17NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
NS16032
|
| gptkbp:IUPACName |
4-phenyl-2,2,4,5-tetramethyl-3-oxazolidinone
|
| gptkbp:legalStatus |
uncontrolled
|
| gptkbp:marketedIn |
gptkb:Argentina
gptkb:Denmark gptkb:Spain |
| gptkbp:sideEffect |
headache
nervousness insomnia |
| gptkbp:soldIn |
gptkb:United_States
|
| gptkbp:usedAs |
stimulant
nootropic |
| gptkbp:bfsParent |
gptkb:NT16000_series
|
| gptkbp:bfsLayer |
8
|